MedVision and AMD form strategic partnershipTelemedicine software developer MedVision of Minneapolis has formed a strategic partnership with diagnostic peripherals supplier American Medical Development (AMD) of Lowell, MA, to provide
Telemedicine software developer MedVision of Minneapolis has formed a strategic partnership with diagnostic peripherals supplier American Medical Development (AMD) of Lowell, MA, to provide telemedicine packages to physicians' groups and healthcare delivery organizations. Physicians and specialists can purchase from MedVision all of the equipment necessary to digitally capture, send, receive, and archive medical images and information.
MedVision's multimedia telemedicine product, VisiTran-MD, is designed to collect, communicate, and store information objects ranging from voice dictation, scanned documents, and live video clips to digitized radiographs and static images. VisiTran-MD also has an object repository to facilitate data storage and retrieval. AMD's medical peripherals deliver video, sound, and data to VisiTran-MD for digital capture. AMD's products include video scopes, electronic stethoscopes, vital-sign capture devices, and other devices that support most medical specialties.
Four Strategies to Address the Tipping Point in Radiology
January 17th 2025In order to flip the script on the impact of the radiology workforce shortage, radiology groups and practices need to make sound investments in technologies and leverage partnerships to mitigate gaps in coverage and maximize workflow efficiencies.
Can Generative AI Facilitate Simulated Contrast Enhancement for Prostate MRI?
January 14th 2025Deep learning synthesis of contrast-enhanced MRI from non-contrast prostate MRI sequences provided an average multiscale structural similarity index of 70 percent with actual contrast-enhanced prostate MRI in external validation testing from newly published research.
Can MRI-Based AI Enhance Risk Stratification in Prostate Cancer?
January 13th 2025Employing baseline MRI and clinical data, an emerging deep learning model was 32 percent more likely to predict the progression of low-risk prostate cancer (PCa) to clinically significant prostate cancer (csPCa), according to new research.